Mercados españoles abiertos en 6 hrs 55 min

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Precio en tiempo real. Divisa en DKK
Añadir a la lista de favoritos
666,70-3,30 (-0,49%)
Al cierre: 4:59PM CEST

Novo Nordisk A/S

Novo Allé 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
http://www.novonordisk.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo45.971

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Lars Fruergaard JorgensenPres, CEO & Member of Management Board35,7MN/A1966
Mr. Karsten Munk KnudsenExec. VP, CFO & Member of the Management Board13,2MN/A1971
Mr. Henrik Ehlers WulffExec. VP, Head of Product Supply, Quality & IT and Member of the Management Board13,9MN/A1970
Ms. Camilla SylvestExec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board13,2MN/A1972
Ms. Monique CarterExec. VP, Head of People & Organisation and Member of Management Board10MN/A1973
Mr. Maziar Mike DoustdarExec. VP, Head of International Operations & Member of the Management BoardN/AN/A1970
Mr. Douglas J. LangaExec. VP, Head of North America Operations & Member of Management BoardN/AN/A1966
Mr. Ludovic HelfgottExec. VP, Head of Biopharm & Member of Management BoardN/AN/A1974
Mr. Martin Holst LangeExec. VP, Head of Devel. & Member of the Management BoardN/AN/AN/A
Mr. Marcus Schindler Ph.D.Exec. VP of Research & Early Devel., CSO and Member of the Management BoardN/AN/A1966
Los importes son a partir de 31 de diciembre de 2020 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en DKK.

Descripción

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Gobierno corporativo

El ISS Governance QualityScore de Novo Nordisk A/S, a día 26 de septiembre de 2021, es 3. Las puntuaciones base son Auditoría: 2; Tablero: 3; Derechos de los accionistas: 9; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.